LifeSci Capital downgraded Merus NV (MRUS) to Market Perform from Outperform on September 29, 2025. The stock is currently priced at $95.73.
This move underscores a shift in sentiment regarding the company's outlook, potentially reflecting concerns over competitive pressures and market conditions affecting performance.
Merus NV, a clinical-stage immuno-oncology company based in Utrecht, engages in the discovery and development of bispecific antibody therapeutics. The firm has a market capitalization of $7.3 billion and reported a trailing twelve-month EPS of -5.34. Upcoming earnings are scheduled for August 3, 2026, with an estimated EPS of -1.40 and revenue of $10.8 million.
Analyst ratings are based on research and financial models, providing insights that may not always align with actual outcomes. Investors should consider multiple factors, including company fundamentals and industry trends, when making decisions. Analyst opinions can evolve as new information becomes available, leading to varying assessments from different analysts.
Recent actions from other analysts include downgrades by Guggenheim, Wells Fargo, Canaccord Genuity, and UBS, all on September 30, 2025.